Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate plus H1 antihistamine vs H1 antihistamine alone in severe refractory chronic idiopathic urticaria
2010-018716-33Phase 3Active
- Sponsor
- CHRU Tours
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of methotrexate in chronic idiopathic urticaria (CIU) (2 arms), sponsored by CHRU Tours. Primary endpoint: Complete remission of urticaria at week 18. Started Aug 2010; status: active.
02
Drugs
methotrexate
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2010-018716-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018716-33.